SoftBank Group Corp. is nearing a deal to invest about $400 million in a health care portal run by Ping An Insurance (Group) Co. ahead of the Chinese company’s initial public offering, according to sources with knowledge of the matter.
The Ping An unit, known as Good Doctor, aims to file an IPO application with the Hong Kong stock exchange as soon as the end of January, the sources said, asking not to be identified discussing a private deal.
It wasn’t immediately clear whether the Good Doctor investment would be made by SoftBank itself or through the Vision Fund that it manages.
China is a key target for SoftBank. The Japanese tech investor run by billionaire Masayoshi Son contributed $5 billion to last year’s $5.5 billion fundraising by Chinese ride-hailing giant Didi Chuxing.
It was also a cornerstone investor in ZhongAn Online P&C Insurance Co.’s Hong Kong IPO. Shares of the insurer have risen 20 percent since their September debut.
Users of Good Doctor’s mobile app can get an online diagnosis within two minutes after posting their symptoms, according to its website. The app also provides health tips, offers purchases of supplements and can keep track of daily workouts.
Other investors had expressed interest in buying stakes in Good Doctor, and details of the fundraising could change, according to the sources. Representatives for Ping An and SoftBank declined to comment.
Good Doctor is preparing for an IPO amid a rally in the benchmark Hang Seng Index, which hit an all-time high this month. First-time share sales in Hong Kong raised $16.5 billion last year, according to data compiled by Bloomberg.
SoftBank has also been weighing investments in other Ping An units, including Lufax, China’s largest online-financing company, and OneConnect, which offers AI-powered services such risk management to financial companies, people familiar with the matter said last month.
The fund would look to take between 5 and 10 percent of the companies, the people said at the time.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.